Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometria
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherap
| Condition(s) | Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Endometrial Cancer Stage |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the blood that is associated with inflammation; redness and swelling). |
| Who can participate | Inclusion Criteria: * Newly diagnosed patients with stages III-IV ovarian or endometrial cancer * Receiving first-line carboplatin and paclitaxel chemotherapy after surgery * ≥18 years, children under the age of 18 will be excluded due to rarity of disease * Physician's clearance to participate in moderate-vigorous intensity exercise * Able to read, write, and understand English * Ability to understand and the willingness to sign an informed consent document * Willing to undergo two venous blood draws for the study Exclusion Criteria: * Pre-existing musculoskeletal, neurological, or cardiorespiratory conditions, as determined by the treating oncologist * Participants with uncontrolled intercurrent illness, as determined by the treating oncologist * Participants with psychiatric illness/soc |
| Ages | 18 Years |
| Sex | Female |
| Lead sponsor | Dana-Farber Cancer Institute |
| Locations | Boston, Massachusetts, United States |
| Start date | 2022-04-02 |
| NCT ID | NCT04997096 |
| Official listing | https://clinicaltrials.gov/study/NCT04997096 |